<DOC>
	<DOCNO>NCT02074605</DOCNO>
	<brief_summary>Interferon alpha approve adjuvant biologic therapy individual diagnose high risk malignant melanoma ( stage 2 3 ) . There evidence interferon adverse cognitive effect patient , limited data . The investigator hypothesis compare patient melanoma receive interferon , patient melanoma treat interferon show objective decrease performance neurocognitive assessment . This study enroll patient melanoma qualify interferon , either decide undergo interferon treatment choose watchful wait instead . All patient assess cognitive test battery twice . Observation patient undergo test first appointment consent study , well next physician visit , approximately 3 month first visit . Interferon patient test immediately prior start interferon , well immediately complete high dose interferon .</brief_summary>
	<brief_title>Cognitive Effects Interferon Patients With Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients diagnose high risk malignant melanoma ( defined American Joint Committee Cancer Stage IIb great ) elect undergo treatment either adjuvant interferon alpha2b , observation . Age 18 year old . Karnofsky performance status great 60 . Fluent English speaker . History neurologic psychiatric disease affect patient 's ability complete protocol test . Clinical radiological evidence brain metastasis . Any condition , opinion investigator make subject unsuitable study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Interferon</keyword>
	<keyword>Cognition</keyword>
</DOC>